BR112017020374A2 - compostos bicíclicos fundidos para o tratamento de doença - Google Patents

compostos bicíclicos fundidos para o tratamento de doença

Info

Publication number
BR112017020374A2
BR112017020374A2 BR112017020374A BR112017020374A BR112017020374A2 BR 112017020374 A2 BR112017020374 A2 BR 112017020374A2 BR 112017020374 A BR112017020374 A BR 112017020374A BR 112017020374 A BR112017020374 A BR 112017020374A BR 112017020374 A2 BR112017020374 A2 BR 112017020374A2
Authority
BR
Brazil
Prior art keywords
disease
treatment
fused bicyclic
bicyclic compounds
compounds
Prior art date
Application number
BR112017020374A
Other languages
English (en)
Inventor
Anthony Pratt Benjamin
Mohan Raju
Original Assignee
Akarna Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akarna Therapeutics Ltd filed Critical Akarna Therapeutics Ltd
Publication of BR112017020374A2 publication Critical patent/BR112017020374A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Abstract

são descritos neste documento compostos bicíclicos fundidos, composições e métodos de uso destes para o tratamento de doença.
BR112017020374A 2015-03-26 2016-03-25 compostos bicíclicos fundidos para o tratamento de doença BR112017020374A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562138725P 2015-03-26 2015-03-26
PCT/IB2016/000606 WO2016151403A1 (en) 2015-03-26 2016-03-25 Fused bicyclic compounds for the treatment of disease

Publications (1)

Publication Number Publication Date
BR112017020374A2 true BR112017020374A2 (pt) 2018-06-05

Family

ID=56072361

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017020374A BR112017020374A2 (pt) 2015-03-26 2016-03-25 compostos bicíclicos fundidos para o tratamento de doença

Country Status (16)

Country Link
US (4) US10421759B2 (pt)
EP (2) EP3274350A1 (pt)
JP (1) JP6843061B2 (pt)
KR (1) KR20180003545A (pt)
CN (1) CN107912042A (pt)
AU (2) AU2016238523A1 (pt)
BR (1) BR112017020374A2 (pt)
CA (1) CA2980394A1 (pt)
CL (1) CL2017002405A1 (pt)
CO (1) CO2017010621A2 (pt)
HK (1) HK1249756A1 (pt)
IL (1) IL254572A0 (pt)
MX (1) MX370897B (pt)
RU (2) RU2021107054A (pt)
SG (2) SG10201908881PA (pt)
WO (1) WO2016151403A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2980394A1 (en) * 2015-03-26 2016-09-29 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
EP3463373A4 (en) * 2016-05-25 2020-04-22 Akarna Therapeutics, Ltd. COMBINATIONS USING FARNESOID X RECEPTOR (FXR) MODULATORS
AU2017270203A1 (en) * 2016-05-25 2019-01-03 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
AU2018275674A1 (en) * 2017-06-02 2020-01-16 Akarna Therapeutics, Ltd. Fused bicyclic compounds
CN108264474B (zh) * 2018-02-09 2019-10-25 浙江师范大学 一种色胺及其衍生物的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
US7595311B2 (en) * 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
BRPI0412262A (pt) * 2003-07-23 2006-09-19 X Ceptor Therapeutics Inc derivados de azepina como agentes farmacêuticos
US7902237B2 (en) 2004-08-10 2011-03-08 Exelixis, Inc. Heterocyclic compounds as pharmaceutical agents
WO2006109633A1 (ja) 2005-04-07 2006-10-19 Daiichi Sankyo Company, Limited 置換インドール化合物
CA2633243C (en) * 2005-12-15 2014-05-27 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
KR20090094125A (ko) 2006-12-08 2009-09-03 엑셀리시스, 인코포레이티드 Ｌｘｒ 및 ｆｘｒ 조절자
US20090137554A1 (en) 2007-10-22 2009-05-28 Wyeth 1,4,5,6-TETRAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY
US20090131409A1 (en) 2007-10-22 2009-05-21 Wyeth 1,4,5,6,7,8-HEXAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY
WO2010036362A1 (en) 2008-09-26 2010-04-01 Wyeth 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors
MY192927A (en) * 2014-11-21 2022-09-15 Akarna Therapeutics Ltd Fused bicyclic compounds for the treatment of disease
AU2015370588B2 (en) * 2014-12-22 2020-07-16 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
CA2980394A1 (en) * 2015-03-26 2016-09-29 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease

Also Published As

Publication number Publication date
MX370897B (es) 2020-01-09
JP6843061B2 (ja) 2021-03-17
US20230002394A1 (en) 2023-01-05
RU2017137366A3 (pt) 2019-07-17
JP2018510876A (ja) 2018-04-19
US20210214362A1 (en) 2021-07-15
WO2016151403A1 (en) 2016-09-29
EP3715348A1 (en) 2020-09-30
AU2016238523A1 (en) 2017-11-09
MX2017012342A (es) 2018-06-11
US20180118752A1 (en) 2018-05-03
US20200079782A1 (en) 2020-03-12
CA2980394A1 (en) 2016-09-29
AU2020256301A1 (en) 2020-11-05
SG11201707610PA (en) 2017-10-30
CN107912042A (zh) 2018-04-13
EP3274350A1 (en) 2018-01-31
US10421759B2 (en) 2019-09-24
CL2017002405A1 (es) 2018-04-27
KR20180003545A (ko) 2018-01-09
RU2017137366A (ru) 2019-04-26
RU2021107054A (ru) 2021-03-31
SG10201908881PA (en) 2019-11-28
IL254572A0 (en) 2017-11-30
CO2017010621A2 (es) 2018-01-31
HK1249756A1 (zh) 2018-11-09

Similar Documents

Publication Publication Date Title
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
BR112017013568A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças
BR112018008326A2 (pt) composições e métodos para o tratamento de câncer
BR112017007170A2 (pt) anticorpos anti-ox40 humanizados e suas utilizações
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
EA201800444A1 (ru) Производные майтанзиноида, их конъюгаты и способы использования
CR20180013A (es) Anticuerpos anti-tau y métodos de uso.
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
EA201791884A1 (ru) Химерные антигенные рецепторы против dll3 и способы применения
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
CL2019001381A1 (es) Método para el tratamiento de glomeruloesclerosis segmentaria focal.
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2016001937A1 (es) Compuestos de benzopirano funcionalizados y uso de los mismos
EA201790156A1 (ru) Азетидинилоксифенилпирролидиновые соединения
BR112018070497A2 (pt) métodos e formulações farmacêuticas para tratamento de condições oculares
BR112018003928A2 (pt) métodos para o tratamento de doenças
CY1122784T1 (el) Αλογονωμενες κιναζολιν-τηf-αμινες ως αναστολεις του ρdε1
BR112018009745A8 (pt) compostos heterocíclicos para o tratamento de doença
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
EA202091567A1 (ru) Химерные белки мти
BR112017019176A2 (pt) processos para a preparação de fluorocetolídeos
EA201691896A1 (ru) Соединения и способы их применения

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2715 DE 17/01/2023.